j health sci med / jhsm Journal of Health Sciences and Medicine 2636-8579 MediHealth Academy Yayıncılık 10.32322/jhsm.1036274 Health Care Administration Sağlık Kurumları Yönetimi Early and late results of intravenous immunoglobulin as potential adjuvant therapies in critically ill COVID-19 patients: a retrospective cohort study https://orcid.org/0000-0003-0658-9138 Gürsoy Canan MUGLA SITKI KOCMAN UNIVERSITY, FACULTY OF MEDICINE https://orcid.org/0000-0003-1499-3747 Oral Tapan Özge MUGLA SITKI KOCMAN UNIVERSITY, FACULTY OF MEDICINE https://orcid.org/0000-0002-9446-2294 Doğan Emrah MUGLA SITKI KOCMAN UNIVERSITY, FACULTY OF MEDICINE https://orcid.org/0000-0003-2696-8696 Pektaş Sinan MUGLA SITKI KOCMAN UNIVERSITY, FACULTY OF MEDICINE https://orcid.org/0000-0001-7721-4582 Demirbilek Semra MUGLA SITKI KOCMAN UNIVERSITY, FACULTY OF MEDICINE 05 30 2022 5 3 794 798 12 14 2021 04 11 2022 Copyright © 2018, Journal of Health Sciences and Medicine 2018 Journal of Health Sciences and Medicine

Introduction: Intravenous immunoglobulin (IVIG), which is one of the adjuvant therapy strategies, has been started to be used in critically ill COVID-19 patients due to its anti-inflammatory and immunomodulatory effects. Material and Method: In our study, it was aimed to evaluate the effect of IVIG used in critically ill COVID-19 patients in the intensive care unit on early laboratory findings and late lung damage. Twenty-two critically ill COVID-19 patients who met the inclusion criteria were included in the study. Laboratory data of the patients who received 0.4 gr/kg/day IVIG for 5 days were analyzed before the treatment and on the 1st and 5th days of the treatment. For the percentage of injured lung areas was evaluated with chest CT.Results: Respiratory rate and CRP decreased with IVIG, while an increase was observed in PaO2/FiO2, WBC, lymphocyte count, D-Dimer and fibrinogen values, which was statistically significant (p

 COVID-19 Immunoglobulin IVIG Pneumonia Grasselli G, Greco M, Zanella A, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med 2020; 180: 1345-55. Salian VS, Wright JA, Vedell PT, et al. COVID-19 Transmission, current treatment, and future therapeutic strategies. Mol Pharm 2021; 18: 754-71. Liu X, Cao W, Li T. High-dose intravenous immunoglobulins in the treatment of severe acute viral pneumonia: the known mechanisms and clinical effects. Front Immunol 2020; 11: 1660. Sakoulas G, Geriak M, Kullar R, et al. Intravenous Immunoglobulin (IVIG) significantly reduces respiratory morbidity in COVID-19 pneumonia: a prospective randomized trial. medRxiv 2020; 20157891. Herth FJF, Sakoulas G, Haddad F. Use of intravenous immunoglobulin (Prevagen or Octagam) for the treatment of COVID-19: retrospective case series. Respiration 2020; 99: 1145-53. Raman RS, Bhagwan Barge V, Anil Kumar D, et al. A Phase II safety and efficacy study on prognosis of moderate pneumonia in coronavirus disease 2019 patients with regular intravenous immunoglobulin therapy. J Infect Dis 2021; 223: 1538-43. Çolak M, Kalemci S, Sarıhan A. Treatment of a case with COVID-19 administering intravenous immunoglobulin. J Glob Antimicrob Resist 2020; 24: 106-7. Suzuki Y, Tanino Y, Nikaido T, et al. Severe coronavirus disease 2019 that recovered from respiratory failure by treatment that included high-dose intravenous immunoglobulin. Intern Med 2021; 60: 457-61. Tatar E, Karatas M, Bozaci I, et al. Intravenous immunoglobulin and favipiravir treatment for a kidney transplant patient with severe COVID-19 pneumonia. Transfus Apher Sci 2020; 59: 1-3. Tabarsi P, Barati S, Jamaati H, et al. Evaluating the effects of intravenous immunoglobulin (IVIg) on the management of severe COVID-19 cases: a randomized controlled trial, Int Immunopharmacol 2021; 90: 107205. Shao Z, Feng Y, Zhong L, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study. Clin Transl Immunol 2020; 9: 1-10. Gharebaghi N, Nejadrahim R, Mousavi SJ, Sadat-Ebrahimi SR, Hajizadeh R. Correction to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis 2020; 20: 1-8. Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis 2020; 7: 1-6. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host & Microbe 2020; 27: 992-1000. Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract 2021; 75: 1-5.